Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2903
Abstract: Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake inhibitors (SSRIs; i.e., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), serotonin and norepinephrine reuptake inhibitors (SNRIs; i.e., desvenlafaxine, duloxetine, levomilnacipran, milnacipran, and venlafaxine), and serotonin modulators with… read more here.
Keywords: htr2a; cyp2d6 cyp2c19; cyp2c19; cyp2c19 cyp2b6 ... See more keywords
Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels - a study based on therapeutic drug monitoring data.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15706
Abstract: AIM Atomoxetine is mainly metabolized by CYP2D6 while CYP2C19 plays a secondary role. It is known that patients carrying genotypes encoding decreased/absent CYP2D6 metabolism obtain higher atomoxetine concentrations and are at increased risk of adverse… read more here.
Keywords: atomoxetine; cyp2d6 cyp2c19; cyp2c19; therapeutic drug ... See more keywords
Pharmacogenetic testing among patients with depression in a US managed care population
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13279
Abstract: Actionable drug–gene pairs relevant to depression treatment include CYP2D6 and CYP2C19 with specific antidepressants. While clinical use of pharmacogenetic testing is growing, little is known about pharmacogenetic testing for depression treatment in managed care. We… read more here.
Keywords: pharmacogenetic testing; managed care; cyp2d6 cyp2c19; depression ... See more keywords
Pharmacogenetic testing revisited: 5′ nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19
Sign Up to like & getrecommendations! Published in 2017 at "Pharmacogenomics and Personalized Medicine"
DOI: 10.2147/pgpm.s131580
Abstract: Due to their involvement in the metabolization of commonly prescribed psychopharmaceutical drugs, the cytochrome oxidase genes CYP2D6 and CYP2C19 are extensive targets for pharmacogenetic testing. The existence of common allelic variants allows the prediction of… read more here.
Keywords: test panels; real time; cyp2d6 cyp2c19; nuclease real ... See more keywords
Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2020.00624
Abstract: Background Drug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6,… read more here.
Keywords: 2c19 2c9; information; cyp2d6 cyp2c19; cyp2d6 2c19 ... See more keywords
The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1080117
Abstract: Pharmacogenetics has potential for optimizing use of psychotropics. CYP2D6 and CYP2C19 are two clinically relevant pharmacogenes in the prescribing of antidepressants. Using cases recruited from the Understanding Drug Reactions Using Genomic Sequencing (UDRUGS) study, we… read more here.
Keywords: adrs ineffectiveness; cyp2d6 cyp2c19; antidepressant response; drug ... See more keywords